MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
ENDRA Life Sciences Total Non Current Liabilities 2011-2026 | NDRA
Annual Total Non Current Liabilities ENDRA Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 843 K | 1.29 M | 192 K | 366 K | - | 609 K | 343 K | - | - | - | 1 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 1 | 520 K |
Quarterly Total Non Current Liabilities ENDRA Life Sciences
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 816 K | 992 K | 758 K | 852 K | 1.29 M | - | 98.4 K | 146 K | 192 K | 237 K | - | - | 366 K | - | - | - | - | - | - | 281 K | 609 K | 628 K | 645 K | 326 K | 343 K | 343 K | 343 K | 343 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 98.4 K | 505 K |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B |  USA |
 |
Agilent Technologies
A
|
3.29 B | $ 115.08 | 0.1 % | $ 35 B | USA |
 |
Celcuity
CELC
|
69.2 K | $ 134.26 | -2.87 % | $ 6.28 B | USA |
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
574 K | $ 9.11 | 79.68 % | $ 12.1 M | USA |
 |
Castle Biosciences
CSTL
|
2.76 M | $ 19.69 | -2.28 % | $ 571 M | USA |
 |
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
2.26 M | $ 17.67 | 3.27 % | $ 544 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
17.9 M | $ 21.54 | -0.42 % | $ 1.15 B | USA |
 |
Guardant Health
GH
|
91.4 M | $ 119.85 | 0.76 % | $ 15 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
10 M | $ 1.8 | -1.1 % | $ 7.96 M | USA |
 |
ICON Public Limited Company
ICLR
|
461 M | $ 113.85 | -2.51 % | $ 9.39 B |  Irlanda |
 |
Illumina
ILMN
|
2.04 B | $ 145.23 | 0.56 % | $ 23.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
161 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
225 M | $ 100.06 | -2.85 % | $ 6.75 B | USA |
 |
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
2.35 B | $ 156.73 | -2.23 % | $ 7.77 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | USA |
 |
Mettler-Toledo International
MTD
|
1.61 B | $ 1 101.33 | -0.16 % | $ 22.7 B |  Schweiz |
 |
Medpace Holdings
MEDP
|
73.8 M | $ 429.11 | -0.85 % | $ 12.4 B | USA |
 |
NeoGenomics
NEO
|
435 M | $ 9.27 | 0.43 % | $ 1.19 B | USA |
 |
National Research Corporation
NRC
|
39.6 M | $ 19.04 | -0.21 % | $ 426 M | USA |
 |
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | USA |
 |
Natera
NTRA
|
124 M | $ 200.91 | -1.12 % | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
107 M | $ 3.85 | 0.79 % | $ 357 M | USA |
 |
Personalis
PSNL
|
639 K | $ 8.94 | 5.55 % | $ 798 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.45 B | $ 26.94 | -0.04 % | $ 25.5 B |  Niderland |
 |
Senseonics Holdings
SENS
|
163 M | $ 6.43 | 1.42 % | $ 268 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.99 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
10.8 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.57 M | $ 2.47 | -0.8 % | $ 5.67 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 258.45 | -0.57 % | $ 21.5 B | USA |
 |
Twist Bioscience Corporation
TWST
|
4.56 M | $ 64.87 | 7.1 % | $ 3.88 B | USA |
 |
Thermo Fisher Scientific
TMO
|
22.5 B | $ 448.18 | -0.02 % | $ 169 B | USA |
 |
Waters Corporation
WAT
|
1.28 B | $ 338.64 | -1.09 % | $ 20.2 B | USA |
 |
Trinity Biotech plc
TRIB
|
106 M | $ 0.65 | 7.49 % | $ 233 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
19.6 M | $ 9.14 | 2.7 % | $ 1.98 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 192.88 | -1.19 % | $ 21.4 B | USA |